

Special Issue

Inflammatory Bowel Diseases: Molecular Mechanisms and Therapies

Message from the Guest Editors

Inflammatory bowel disease (IBD) is a rapidly developing field of gastroenterology and immunology. The purpose of this issue of Biomedicines is to review the current, imminent and future therapeutic armamentarium in IBD from the bench to the bedside. Each review will relate to a different therapeutic class and briefly describe the role of the therapeutic target in the inflammatory cascade, different approaches to manipulating the target, and the resultant drug, with a more in-depth analysis of the efficacy and safety of the drug. The review will include older drugs such as corticosteroids, thiopurines and methotrexate; established biologic therapies such as anti-TNF agents, vedolizumab and ustekinumab; newer small molecules such as tofacitinib; and newer biological agents and small molecules currently in phase 3 testing. Further reviews will relate to other therapies such as antibiotics and microbiome manipulation, nutritional therapy, and stem cells, both in perianal disease and stem cell transplants.

- inflammatory bowel disease
- Crohn's disease
- ulcerative colitis
- therapeutics
- biologic
- microbiome

Guest Editors

Prof. Ariella Bar-Gil Shitrit

Department of Gastroenterology, Shaare Zedek Medical Center,
Faculty of Medicine, Hebrew University, Jerusalem, Israel

Dr. Oren Ledder

The Juliet Keidan Institute of Paediatric Gastroenterology, Shaare Zedek Medical Center; Department of Pediatric Gastroenterology, Assuta Hospital Ashdod Faculty of Medicine, Hebrew University, Jerusalem, Israel

Deadline for manuscript submissions

closed (31 October 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/78676

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).